A study to see if HIV protease inhibitors increased risk of liver toxicity in persons coinfected with hepatitis C unexpectedly found that they may reduce liver damage from the disease. An FDA advisory committee will hold a one-day public hearing on this important new antiretroviral. Too much homocysteine in the blood is associated with an increased risk of heart and circulatory diseases.
Blood tests can detect the problem, and it can often be treated with nutrition and supplements.
Here is some background on this potential approach to reducing cardiovascular risk. A new treatment activist coalition, formed in mid August, will develop national strategies, plan mentoring of new activists, and help persons with HIV and activists find consensus and work together on issues involving treatment research and access to care. The North American AIDS Treatment Action Forum will be held December 2-5 in Vancouver. But for those needing scholarships, the deadline to apply for a scholarship is now.